FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide

Table 1 Relationship between FXYD2 mRNA expression and clinical features in 516 glioma patients

Parameter	Variable	N	FXYD2 mRNA expression				χ2	P value
Parameter	Variable	N	Low	%	High	%	χ2	P value
Sex	Female	225	115	51.1	110	48.9	0.197	0.657
Sex	Male	291	143	49.1	148	50.9
Age^a	< 43	238	119	50.0	119	50.0	0.000	1.000
Age^a	≥ 43	278	139	50.0	139	50.0
Progression status	Primary	301	129	42.9	172	57.1	14.743	0.000
Progression status	Recurrent	215	129	60.0	86	40.0
Histopathological types (HE)^b	oligodendroglioma	114	31	27.2	83	72.8	31.937	0.000
	astrocytoma	218	117	53.7	101	46.3
	glioblastoma	184	110	59.8	74	40.2
IDH mutation status	Wildtype	224	155	69.2	69	30.8	58.347	0.000
IDH mutation status	Mutant	292	103	35.3	189	64.7
1p/19q codeletion status	Non-codel	401	231	57.6	170	42.4	41.636	0.000
1p/19q codeletion status	Codel	115	27	23.5	88	76.5
MGMT methylation_status	methylated	244	115	47.1	129	52.9	0.564	0.453
	un-methylated	169	86	50.9	83	49.1
	NA	103	57	55.3	46	44.7
2021 WHO classification	Oligodendroglioma, IDH-mutant and 1p/19q-codeleted	114	31	27.2	83	72.8	64.092	0.000
	Astrocytoma, IDH-mutant	186	77	41.4	109	58.6
	Glioblastoma, IDH-wildtype.	147	97	66.0	50	34.0
	Astrocytoma, IDH-wildtype (NEC)^c	69	53	76.8	16	23.2
2021 WHO grade	2	134	60	44.8	74	55.2	10.951	0.004
	3	198	88	44.4	110	55.6
	4	184	110	59.8	74	40.2
Complete excision	No	126	61	48.4	65	51.6	0.095	0.758
	Yes	372	186	50.0	186	50.0
	NA	18	11	61.1	7	38.9
Radiotherapy	No	108	54	50.0	54	50.0	0.000	1.000
Radiotherapy	Yes	408	204	50.0	204	50.0
Chemotherapy	No	124	60	48.4	64	51.6	0.170	0.680
Chemotherapy	Yes	392	198	50.5	194	49.5

^aThe patients were divided into two groups according to the median age of 43 years
^bThe histological and pathological types were determined based exclusively on morphological features on hematoxylin-eosin sections
^cNEC means that the necessary molecular markers have been successfully detected, but the results cannot be classified into the current who glioma classification

ISSN: 1471-2377